The top 10 pipeline blowups, set­backs and sna­fus for H1 2019

These days, when I start writ­ing up a half year’s sup­ply of the top sna­fus in drug R&D, I start by search­ing the archives on Alzheimer’s. So much has gone so bad about this field for so long that it has be­come a reg­u­lar and re­li­able play­er in the area of re­search set­backs. 

That’s a trend with legs. 

I usu­al­ly get tagged with some ac­cu­sa­tion of schaden­freude when it comes to this se­ries — in one of the lighter frays of­fered on Twit­ter. In fact, if you look close­ly you’ll find valu­able lessons in­clud­ed for every R&D ex­ec and in­vestor who likes to watch the field — if they care to learn. But while the ed­u­ca­tion can be had for free, it still amazes me how raw and un­ex­pect­ed the fail­ure is when it does come.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.